Literature DB >> 2104682

Characterization of an HIV-1 point mutant blocked in envelope glycoprotein cleavage.

H G Guo1, F M Veronese, E Tschachler, R Pal, V S Kalyanaraman, R C Gallo, M S Reitz.   

Abstract

The envelope proteins of retroviruses are derived from a polypeptide precursor protein by cleavage adjacent to a cluster of basic amino acids. Site-specific mutagenesis was used to construct a mutant of the human immunodeficiency virus type 1 (HIV-1) in which the arginine residue at the carboxy-terminus of the gp120 was changed to a threonine residue. This single substitution was sufficient to abolish all detectable cleavage of the gp160 envelope precursor polypeptide as well as virus infectivity. The gp160 was produced in normal quantities from a biologically active clone of the mutant virus after transfection into cos-1 cells. The mutant gp160 contained N-linked oligosaccharide chains with mannose-rich cores similar to those of the gp160 produced by the wild-type clone. Immunofluorescence assays showed that gp160 was transported to the surface of transfected CD4+ HeLa cells. No envelope proteins of known size could be detected in the media of cells transfected with the mutant virus, suggesting that functional virions were not formed. Binding of the mutant gp160 to the CD4 receptor molecule was unimpaired. Despite this and the presence of gp160 on the cell surface, neither growth of mutant-transfected CD4+ HeLa cells nor cocultivation of transfected cos-1 cells with H9 cells resulted in significant syncytium formation. The data indicate that the carboxy-terminal arginine residue of HIV-1 gp120 is necessary for envelope protein cleavage and suggest cleavage is important in the virus life cycle in both functional virus release and membrane fusion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104682     DOI: 10.1016/0042-6822(90)90070-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  27 in total

1.  A protein-based therapeutic for human cytomegalovirus infection.

Authors:  F Jean; L Thomas; S S Molloy; G Liu; M A Jarvis; J A Nelson; G Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

3.  Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function.

Authors:  R J Wool-Lewis; P Bates
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

4.  Characterization of the R572T point mutant of a putative cleavage site in human foamy virus Env.

Authors:  A Bansal; K L Shaw; B H Edwards; P A Goepfert; M J Mulligan
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with human immunodeficiency virus type 1.

Authors:  T D Duensing; H Fang; D W Dorward; S H Pincus
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  A furin-defective cell line is able to process correctly the gp160 of human immunodeficiency virus type 1.

Authors:  Y Ohnishi; T Shioda; K Nakayama; S Iwata; B Gotoh; M Hamaguchi; Y Nagai
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

Review 7.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

8.  Structural features influencing hemagglutinin cleavability in a human influenza A virus.

Authors:  Y Kawaoka
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  Characterization of a cleavage mutant of the measles virus fusion protein defective in syncytium formation.

Authors:  G Alkhatib; J Roder; C Richardson; D Briedis; R Weinberg; D Smith; J Taylor; E Paoletti; S H Shen
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

10.  Delayed cytopathicity of a feline leukemia virus variant is due to four mutations in the transmembrane protein gene.

Authors:  E Thomas; J Overbaugh
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.